Updates in the Journey for Disease-Modifying Therapies for Alzheimer Disease

Released On
December 14, 2020

Expires On
December 14, 2021

Media Type
Internet

Completion Time
75 minutes

Specialty
Geriatric Medicine, Neurology, Primary Care

Topic(s)
Alzheimer's, Dementia, Geriatric Medicine

Scroll to the Bottom of this Information to Begin this Course

This activity is provided by Physicians’ Education Resource®, LLC.

This activity is supported by an educational grant from Biogen.

Credit Available

  • Physicians — maximum of 1.25 AMA PRA Category 1 Credit(s)

All other healthcare professionals completing this course will be issued a statement of participation.

Target Audience

This online educational activity is directed toward neurologists, primary care physicians, physician assistants, and nurses specializing in neurologic disorders.

Program Overview

This online, on-demand virtual symposium brings together renowned experts in Alzheimer disease, the most common cause of dementia among older adults. In this educational program, faculty discuss current and emerging biomarkers that can aid in earlier diagnosis. Current treatments that address symptoms will be reviewed. Pathophysiologic targets for agents in clinical trials are described, followed by presentation of data on second-generation immunotherapies. The program will conclude with practical approaches to manage comorbidities and improve quality of life for both patients and caregivers, along with the latest evidence for a healthy-brain lifestyle.

This educational activity is an archive of the live virtual symposium held on November 24, 2020.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Explain neurodegenerative alterations that are considered the hallmarks of AD versus different neurodegenerative disorders
  • Implement screening and diagnostic protocols in clinical practice to ensure early detection of AD
  • Analyze key data on new and emerging treatment options for AD to properly educate patients and impacted caregivers
  • Construct team-based strategies to improve coordination of care for patients with AD

Chair

Richard S. Isaacson, MD, FAAN

Richard S. Isaacson, MD, FAAN

Director, Alzheimer’s Prevention Clinic
Associate Professor of Neurology
New York-Presbyterian Hospital/Weill Cornell Medicine
New York, NY

Faculty

Marc E. Agronin, MD

Marc E. Agronin, MD

Senior Vice President, Behavioral Health
Chief Medical Officer, MIND Institute
Miami Jewish Health
Affiliate Associate Professor of Psychiatry and Neurology
University of Miami Miller School of Medicine
Miami, FL

Sharon Cohen, MD, FRCPC

Sharon Cohen, MD, FRCPC

Neurologist and Medical Director
Toronto Memory Program
Toronto, Canada

Accreditation Statement

Physicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 1.25  AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosures of Conflicts of Interest

In accordance with ACCME guidelines, PER® has identified and resolved all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Richard S. Isaacson, MD, FAAN

  • No relevant financial relationships with commercial interests

Marc E. Agronin, MD

  • Grant/Research Support: Biogen; Lilly, Roche, Alzheon, Sage Therapeutics, Johnson & Johnson
  • Consultant: Biogen, Lilly
  • Speakers’ Bureau: Biogen

Sharon Cohen, MD, FRCPC

  • Grant/Research Support: AbbVie, AgeneBio, Alector, Anavex Life Sciences, Biogen, Certification Commission for Healthcare Interpreters, Eisai, Janssen Pharmaceuticals, Lilly, RetiSpec, Vielight
  • Consultant: Alnylam Pharmaceuticals, Biogen, Cogstate, ProMIS Neurosciences, RetiSpec
  • Content: investigational/unapproved: aducanumab, BAN2401, other Alzheimer disease investigational products

The staff of Physicians’ Education Resource®, LLC (PER®), have no relevant financial relationships with commercial interests to disclose.

Instructions for Participation and Credit

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:

  1. Complete the activity (including pre- and postactivity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.
You may immediately download your certificate.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.